Biopharmaceutical
– Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant allele burden and bone marrow fibrosis, key markers of disease modification – – AJ1-11095 is currently in a Phase 1 clinical trial in patients with myelofibrosis, previously treated with a type I JAK2 inhibitor – Excerpt from the…
Read More
Excerpt from the Press Release: EMERYVILLE, Calif.–(BUSINESS WIRE)–Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that an independent Data Safety Monitoring Board (DSMB) has completed its review of safety data from the Phase I…
Read More
First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI’s registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global, complementary superiority trials using a novel ordinal diabetic retinopathy severity scale (DRSS) primary endpoint Targeting a broad diabetic retinopathy (DR) label by including patients with non-center-involved diabetic macular edema…
Read More
Consistent, significant tumor reductions across all ACP patients mark the second low-complexity Wnt/β-catenin-driven tumor subgroup – alongside desmoid tumors – showing uniform monotherapy activity in multiple patients treated with FOG-001 Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced…
Read More
78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in VK2735 Excerpt from the Press Release:v SAN DIEGO, Nov. 19, 2025 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and…
Read More
Excerpt from the Press Release: PRINCETON, N.J., Nov. 19, 2025 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has completed the planned enrollment of 50 patients necessary for the interim…
Read More
— Final ALPHA-STAR Phase 1b/2 Results from the Full-Enrollment Population (n=29) Remain Highly Consistent with Prior Results from the Target-Enrollment Population (n=16), Demonstrating Strong Efficacy, Favorable Safety, and Potential for Infrequent Dosing — — Phase 3 ALPHA-ORBIT Trial for Navenibart is Progressing as Planned with Topline Results Anticipated in Early 2027; First Patient Now Enrolled…
Read More
Excerpt from the Press Release: BOSTON and SINGAPORE, Nov. 06, 2025 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, and ImmunoScape, Pte. Ltd, a biotechnology company developing next-generation T…
Read More
The next 6 months of scientific studies to investigate the utility in early stage, premalignant lesions of Toragen’s first-in-class small molecule, oral drug candidate TGN-S15 is funded by the Gates Foundation. Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Toragen, Inc., an oncology biopharmaceutical company focused on the development of TGN-S15, their oral, small molecule drug…
Read More
CuraAX aims to address debilitating blood pressure drops and cognitive symptoms of nOH Excerpt from the Press Release: SAN CARLOS, Calif.–(BUSINESS WIRE)–CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced dosing of the first patient with CuraAX (CST-3056) in a Phase 2a proof-of-concept trial…
Read More